Table 2 |
|
|
Advantages by route of administration |
|
|
Route |
Advantages |
|
|
|
|
Subcutaneous |
Patient control |
|
Lack of associated (such as office-related) costs |
|
|
No need for patient to travel to office |
|
|
Intravenous |
Physician control |
|
Automatic compliance |
|
|
Dose not limited by volume |
|
|
Continuous titration available |
|
|
Rapid onset of action |
|
|
Reimbursed by Medicare |
|
|
|
|
|
Schwartzman and Morgan Arthritis Res Ther 2004 6(Suppl 2):S19 doi:10.1186/ar996 |
|